NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
UNITED STATES |
OMB APPROVAL |
OMB Number: |
3235-0080 |
Expires: |
March 31, 2018 |
Estimated average burden |
hours per response: |
1.7 |
|
|
SECURITIES AND EXCHANGE COMMISSION |
Washington, D.C. 20549 |
FORM 25 |
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
|
Commission File Number |
001-36242 |
|
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
|
Address: |
11455 El Camino Real, Suite 310 |
|
Del Mar |
CALIFORNIA |
92130 |
Telephone number: |
| 18,584,127,950 |
|
(Address, including zip code, and telephone number, including area code, of Issuer's
principal executive offices)
|
Common stock |
(Description of class of securities)
|
|
Please place an X in the box to designate the rule provision relied upon to strike
the class of securities from listing and registration:
|
|
Pursuant to the requirements fo the Securities Exchange Act of 1934,
Nasdaq Stock Market LLC
certifies that it has reasonable grounds to believe that it
meets all of the requirements for filing the Form 25 and has caused this notification to be
signed on its behalf by the undersigned duly authorized person.
|
2024-03-20 |
By |
Aravind Menon |
|
Hearings Advisor |
Date |
|
Name |
Title |
|
1 |
Form 25 and attached Notice will be considered compliance with the provisions of
17 CFR 240.19d-1 as applicable. See General Instructions.
|
|
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
|
Delisting Determination, The Nasdaq Stock Market, LLC, March 21, 2024,
DMK Pharmaceuticals Corporation.
The Nasdaq Stock Market LLC (the Exchange) has determined to remove
from listing the securities of DMK Pharmaceuticals Corporation,
effective at the opening of the trading session on April 1, 2024.
Based on review of information provided by the Company, Nasdaq Staff
determined that the Company no longer qualified for listing on the
Exchange pursuant to Listing Rule 5550(b)(2).
The Company was notified of the Staff determination on October 11,
2023. On October 18, 2023, the Company exercised its right to appeal
the Staff determination to the Listing Qualifications Hearings Panel
(Panel) pursuant to Listing Rule 5815.
On October 18, 2023, the Company received an additional delist
determination for its failure to meet the requirements in Listing
Rule 5550(a)(2).
On January 9, 2024, upon review of the information provided by the
Company, the Panel determined to grant the Company request to remain
listed in the Exchange subject to a series of milestones.
On February 6, 2024, the Company witdrew its appeal. The Company
securities were suspended on February 7, 2024. The Staff determination
to delist the Company securities became final on March 22, 2024.